Sleep medication use in children is a clinically sensitive area where evidence often lags behind practice. Understanding real-world prescription patterns matters because pediatric populations are pharmacologically distinct from adults, and many hypnotics carry poorly characterized long-term developmental risks. This large-scale Japanese claims analysis offers a rare population-level snapshot of how clinicians actually navigate those decisions.
Drawing on claims data from over 21,000 patients aged 0–17 receiving first-time hypnotic prescriptions between mid-2021 and mid-2023, the study mapped drug class selection across four age bands. Melatonin dominated prescribing in younger children (ages 0–11), accounting for roughly 34% of all initial prescriptions and tending toward longer treatment durations. Melatonin receptor agonists (MRAs) such as ramelteon were used across the full age spectrum at 31%, while dual orexin receptor antagonists (DORAs) — a newer class — concentrated among adolescents aged 15–17 at nearly 19%. Older sedative-hypnotic classes, Z-drugs and benzodiazepines, together accounted for 16% of prescriptions. Psychiatric comorbidity was strikingly prevalent: autism spectrum disorder appeared in 32.5% of patients, followed by depression (23.4%), ADHD (19.8%), and anxiety disorders (18.2%).
The age-stratified pattern reflects a clinically rational hierarchy — melatonin and MRAs carry more favorable safety profiles for younger patients, while DORAs represent a modern, mechanistically distinct option better studied in adults but increasingly explored in adolescents. The high prevalence of neurodevelopmental and psychiatric comorbidities is unsurprising given that sleep disturbance is near-universal in autism and ADHD, yet it underscores that pediatric hypnotic use rarely addresses isolated insomnia. A key limitation is the descriptive, cross-sectional design: claims data cannot capture clinical rationale, adherence, or outcomes, and Japan's prescribing norms may not generalize globally. Still, this is one of the larger pediatric hypnotic datasets published, offering a useful baseline as DORA use expands into younger age groups.
